Group 1 - The company has received the approval notice for the listing application of the chemical raw material drug Difluprednate from the National Medical Products Administration (NMPA) [1][3] - Difluprednate is a topical corticosteroid used to suppress inflammation caused by various irritants, primarily available in the form of eye drops for treating inflammation and pain related to eye surgeries [2][3] - The global sales figures for Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024, indicating a potential market opportunity for the company [3] Group 2 - The approval of the raw material drug will enhance the company's product portfolio and leverage its integrated advantages in raw material and formulation production, aiding in business expansion [4] - The company has invested approximately 2.6 million yuan in the research and development of the Difluprednate raw material project [3]

Core Viewpoint - The company Tianyao Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Difluprednate, a topical corticosteroid drug that can inhibit inflammation caused by various irritants [1] Group 1: Product Information - Difluprednate is primarily available in the form of eye drops and is used to treat inflammation and pain associated with eye surgeries [1] - According to the IQVIA database, the global sales of Difluprednate formulations are projected to be $49 million in 2023 and $41 million in 2024 [1]